Controlled Substance Monitoring Systems are state-run electronic databases that track prescriptions for drugs in Schedules II through V. These programs collect data from pharmacies, clinics, and prescribers and share that information with authorized healthcare workers. The goal is to stop prescription drug abuse, find possible drug diversion, and promote safe prescribing and dispensing.
For example, California runs the Controlled Substance Utilization Review and Evaluation System (CURES), managed by the California Department of Justice (DOJ). CURES tracks prescriptions for controlled substances across the state. The data helps healthcare professionals, regulatory agencies, and law enforcement work to reduce opioid misuse and make sure patients get safe and proper medications.
Healthcare providers who can prescribe controlled substances must register and use CURES to check patients’ prescription histories before giving new prescriptions. This helps find patients who might be at risk for overdose or misuse by showing possible problems like overlapping prescriptions from different providers or risky drug combinations, such as opioids with benzodiazepines.
Keeping these controlled substance monitoring programs running and improving needs steady funding. Systems like CURES get money from fees collected yearly when prescribers and dispensers renew their licenses. These fees pay for regulation, technology upkeep, data security, updates, and operations important for the program’s success.
California’s example is clear. Starting July 1, 2025, the annual fee for CURES will rise from $9 to $15. Because most licenses renew every two years, healthcare providers will get renewal notices asking for $30 to cover two years of CURES access and maintenance. This change matches the increasing costs to keep the system secure, correct, and on time, including following new data rules and improving technology.
Updating these fees ensures enough money to keep the system working well. Without proper fees, states could struggle to keep technology systems running, enforce timely data reporting, or follow laws about opioid prescribing and controlled substance monitoring.
Programs like CURES are a key part of state and national plans to stop opioid overdose deaths and addiction. They let providers check drug histories before prescribing opioids. This helps find risky patterns before harm happens.
The Centers for Disease Control and Prevention (CDC) advises clinicians to check PDMP data before every opioid prescription and sometimes during treatment. This helps find patients taking high opioid doses, dangerous drug mixes, or several overlapping prescriptions, which raise overdose risk.
PDMP data help make clinical decisions that can save lives. Providers might offer naloxone (a drug that reverses opioid overdose) or refer patients for addiction treatment based on PDMP findings. These programs also give information for open and trustful talks about opioid therapy safety.
Money from updated fees directly supports these health goals by keeping the system running, data accurate, and technicians trained. It also helps states meet laws and update how data is shared.
Multiple agencies watch over controlled substances, including state medical and pharmacy boards, the Department of Consumer Affairs, and law enforcement. These groups use PDMP data to check if prescribing laws are followed and to investigate possible fraud, diversion, or abuse.
California’s CURES requires pharmacies and dispensers to send data within one working day after giving controlled substances. This recent rule makes sure prescribers get current data before issuing new prescriptions.
On August 1, 2024, California dispensers had to switch to ASAP 2020 Version 4.2B data formats. This update improves data quality and standardization. Following these technical rules needs ongoing system updates and staff training, which are supported by fees collected.
Without enough funding, delays, wrong data, or submission errors could happen. These issues would hurt patient care and regulation. Fee increases help cover the cost of technology and operations needed to meet state laws and federal rules, including rules for electronic prescribing of controlled substances.
Medical practice administrators and IT managers need to know about PDMP fee changes and compliance rules. They handle budgets, license renewals, and tech systems that connect with PDMPs.
Fee updates affect licensing costs for prescribers and pharmacists in the practice. Admin staff must add these fee changes when handling credentialing and make sure all staff who handle controlled substances are properly registered with the PDMP system.
IT teams must ensure electronic health record (EHR) systems and pharmacy software follow reporting standards like ASAP 4.2B and connect securely with the PDMP. They work with software vendors and training programs to keep data reporting smooth. This lowers compliance risks and helps clinical work run well.
Day-to-day, these teams make sure prescribers use the PDMP as required, avoiding care interruptions and protecting the practice from regulatory penalties.
Artificial intelligence (AI) and workflow automation can help make controlled substance monitoring more efficient in medical practices.
AI tools can automatically check PDMP databases while prescribing. They can alert clinicians right away about risks like duplicate therapies, high opioid doses, or risky drug combinations. This reduces manual work and helps providers prescribe more safely. These tools work within the electronic health record.
Automation can also simplify compliance. For example, it can send automatic reminders for license renewals and PDMP fee updates, or notify about delegate access renewals. Automated systems ensure dispensers submit data on time, reducing late submissions.
AI can help spot unusual prescribing patterns for review by compliance officers or healthcare administrators, which may point to possible abuse or diversion early. This support helps regulatory goals and lets practitioners focus on patient care.
For IT teams, adding AI-enhanced PDMP tools to current clinical software can improve user experience and reduce workflow interruptions. This helps meet the need for fast and accurate drug data access emphasized by programs like CURES.
Many states outside California have similar PDMP fees and reporting rules. Knowing California’s system can help administrators prepare for possible fee and rule changes in their areas.
Updating fees for controlled substance monitoring systems is needed to pay for technology updates, keep up with rules, and help prevent opioid addiction. Systems like California’s CURES show how fee changes support timely data reporting, system upgrades, and better access for healthcare providers.
Medical practice administrators, owners, and IT managers should be aware of these fee and rule changes. Using technology like AI and automation can make controlled substance monitoring easier and safer for prescribers and their teams.
These efforts help keep patients safe and support public health by maintaining tools that reduce prescription drug abuse while allowing proper medical use of controlled substances.
The mission is to protect healthcare consumers and prevent harm through proper licensing and regulation of physicians, surgeons, and allied healthcare professionals, enforcing the Medical Practice Act, and promoting access to quality medical care through licensing, policy, and regulatory functions.
By licensing and regulating healthcare professionals, enforcing the Medical Practice Act objectively, and promoting access to high-quality medical care through its regulatory and policy roles.
Patients can use online license verification tools provided by the Medical Board of California or use the physician name search feature to check license status and be informed about their healthcare providers.
Collaboration ensures uninterrupted access to necessary medications by facilitating timely prescription validation, authorization, and transfer of prescriptions, which is critical to maintaining continuity of care when pharmacies close.
Closures have disrupted timely access to prescriptions across California, increasing the need for clear communication and cooperation between prescribers and pharmacists to minimize negative effects on patient care.
Starting July 1, 2025, the CURES fee will increase from $9 to $15 annually, primarily affecting prescribers authorized to handle controlled substances, supporting the state’s opioid addiction prevention efforts.
It funds the Department of Justice’s regulatory costs for operating CURES, which helps monitor and control prescription drug abuse and opioid addiction by tracking controlled substance management.
Effective January 1, 2025, the program is being transferred from the Medical Board of California to the Board of Psychology, shifting regulatory responsibility to the latter under Senate Bill 815.
No, existing registrations and practice authorizations remain valid initially, with the Board of Psychology considering future law changes and managing inquiries post-transfer.
Inquiries can be directed via phone at 916-574-7720 or toll-free at 866-503-3221, or through the Board of Psychology’s online contact form starting January 1, 2025.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
